Citizens JMP raised the firm’s price target on Taysha Gene Therapies (TSHA) to $8 from $6 and keeps an Outperform rating on the shares. Taysha Gene Therapies reported Q3 results and provided a safety update on 12 dosed patients and a finalized statistical analysis plan that is achievable based on available data, the analyst tells investors in a research note. Finalized REVEAL plans have weathered the regulatory storm, and Citizens believes the protocol is currently the best approach in Rett, giving Taysha a significant competitive advantage.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies Advances TSHA-102 Program
- Taysha Gene Therapies’ Earnings Call Highlights Progress and Challenges
- Taysha Gene Therapies: Advancing REVEAL Study and Mitigating Regulatory Risks Earns Buy Rating
- Taysha Gene Therapies files automatic mixed securities shelf
- Taysha Gene Therapies Amends Sales Agreement, Expands Offering